IFNG and glioma: Adoptive immunotherapy research, particularly CAR-T cells engineered against ICOS and EGFRvIII, shows promise in vitro against glioma cells (U87) and in xenograft mouse models, marked by IFN-γ secretion and tumor growth inhibition [54, 55].